Market this week (2022.01.03-2022.01.07)
This week, the pharmaceutical sector fell 4.55%, 2.17 percentage points lower than the Shanghai and Shenzhen 300 index. In the previous weekly report, we discussed the generic cro track from the listing of Baicheng pharmaceutical to the emerging boom. This week, we continue to dig into the high boom track. Its essence is that as an important part of China Meheco Group Co.Ltd(600056) industrial reform, the characteristic Chinese pharmaceutical CXO has built a drug MAH license transformation platform to promote the realization of “horizontal integration and vertical chain integration” of China’s MAH license.
Under MAH licensed business format, China Meheco Group Co.Ltd(600056) industrial pattern changes quietly. In March 2020, the state Market Administration issued a document to fully implement the drug marketing license holder (MAH) system. Mah system not only realizes the separation of research, production and marketing, but also brings new opportunities to research, production and marketing. Pharmaceutical care integrated CXO has built a drug MAH license transformation platform for Chinese and foreign biomedical enterprises. With MAH license as the core, it runs through the whole industrial chain of cro R & D and CMO production, allocates high-quality industrial chain resources, constructs MAH whole industry ecosystem, forms a strong agglomeration effect leading development, and promotes China’s MAH license to realize “horizontal integration and vertical chain integration”.
It is not only an outsourcer, but also a developer. Independent project varieties inject new momentum into China Meheco Group Co.Ltd(600056) . Compared with the innovative drug CXO, CXO with Chinese characteristics established a rich independent R & D pipeline at the beginning of its establishment, In “entrusted service + R & D technology achievement transformation” “Achieve stable and high growth under the two wheel drive. CXO with Chinese characteristics closely tracks the pharmaceutical market demand and carries out independent research and development for drug varieties with high market value. After obtaining phased technical research and development results, it recommends them to customers according to market demand and development plan. After successful recommendation, the customer entrusts the company to continue follow-up research on the basis of previous research and development results To shorten the whole R & D cycle and pay a higher premium to the company, so as to realize the company’s profitability. This model greatly shortens the R & D cycle of the drug, ensures the efficiency and quality of R & D, and further enhances customer stickiness; At the same time, the company can obtain a higher premium, realize greater value and achieve the integration and sharing of the company and customers.
This week’s stock recommendations focus on Portfolio:
Growth Portfolio: Pharmablock Sciences (Nanjing) Inc(300725) , Beijing Balance Medical Technology Co.Ltd(688198) , Eyebright Medical Technology(Beijing) Co.Ltd(688050)
Robust combination: Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Baicheng pharmaceutical
Elastic combination: Chongqing Taiji Industry (Group) Co.Ltd(600129) , Jianmin Pharmaceutical Group Co.Ltd(600976) , Tianjin Chase Sun Pharmaceutical Co.Ltd(300026)
Risk tips: risk of policy changes in the pharmaceutical industry; Policy risk; Other systemic risks.
